Abiomed, Inc. Preliminary Revenue Results for the Third Quarter of Fiscal Year 2017; Reaffirms Earnings Guidance for the Fiscal Year 2017
The company is maintaining its fiscal year 2017 revenue guidance of $435 million to $445 million, an increase in revenue of 32% to 35% from the prior year. The company is also maintaining its fiscal year guidance for GAAP operating margin to be in the range of 18% to 20%. For third quarter of fiscal 2017, the US patient usage grew 32% in comparison with same period of fiscal 2016.